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Background
Behçet Disease (BD) is exceptionally observed in chil-
dren and raises diagnosis problems because there is no
specific biologic marker. Sets of clinical criteria have
been proposed for adult patients only.
Aim
Is to set-up an international cohort of patients suspected
with BD and selected on homogenous criteria. The
cohort is aimed at defining an algorithm for definition
of the disease in children, reflecting the natural history.
Methods
Centers specializing in PedBD have been called to colla-
borate documenting their patients into a single online
database. An international expert committee has defined
inclusion criteria as follows: first sign before 16 years,
new patient or patient followed since less than 3 years,
patient followed 4 years, consent obtained, and recur-
rent oral aphthosis [OA] (more than 3 attacks/year)
associated to at least one of following symptoms: genital
ulceration, erythema, folliculitis, pustulous/acneiform
lesions, positive pathergy, uveitis, venous/arterial throm-
bosis, family history. Data are updated every year and
patient’s files are classified by the expert committee into
3 groups: definite, probable and not BD. Statistical ana-
lyses are performed to compare the 3 groups.
Results
In April 2011, 171 patients (85M/86F) from 20 centres
of 11 countries have been included. Mean age at inclu-
sion was 12.4y, at first symptom 7.4y and at BD
suspicion 11.3y. 44 % of patients had only 1 symptom
associated with OA, 27% had 2 and 29% had at least 3.
166 first visits have been done, 85% were receiving treat-
ment; 26% had a family history of BD, 22% were
HLAB51. 102 patients underwent first year visit, 65 had
no new symptom, 25 had one, 11 had 2 and 1 had 3. 51
two year visits have been done, 40 patients had no new
symptom, 12 had 1 and 6 had 2. The expert committee
has examined 119 files (in which 13 twice) and classified
63 as definite and 54 as probable. Two were classified as
not BD. 50/63 definite BD fulfilled the ISG criteria and
13/54 probable BD meet the international criteria.
Conclusion
There is an increase of the number of patients classified
in the BD group although they do not fill the interna-
tional BD classification criteria.
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